Grant: Engage Grants Program
McMaster University
$25,000.00
Evaluation and characterization of novel inhibitors of beta-lactamases
EF 2013-14
Résumé
Resistance to antibiotics is a growing crisis that has major implications for the healthcare, agricultural andpharmaceutical sectors. Despite a tremendous need for new drugs and there are few new leads being pursued bythe traditional large pharmaceutical industry. This void creats a great opportunity for Small to Medium sizedEntities (SMEs) in this area. NAEJA Pharmaceuticals of Edmonton, AB has developed a collection ofproprietary and novel lead molecules that inhibit ß-lactamases, enzymes that inactivate the penicillin,cephalosporin and penem antibiotics that represent ~50% of the antibiotic drugs in current clinical use. Suchinhibitory molecules could form the basis of drug formulations where the inhibitor of ß-lactamase enzymes isadministered together with a ß-lactam drug. This approach has proven clinical utility and has been successfullydeployed for the treatment of drug resistant infections including several ""blockbuster"" drug combinations suchas Augmentin (a combination of amoxicillin and the ß-lactamase inhibitor clavulanic acid). In order to movethese lead candidates forward, NAEJA needs to have a better understanding of the molecular mechanisms ofß-lactamase inhibition these compounds and their roles in blocking antibiotic resistance in cells, expertise thatis the core of over 20 years of research in the Wright lab. This new partnership will enable NAEJA to assessthe value of their lead molecules and select one as a clinical candidate for downstream drug development andclinical trials.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
446463-2013
Name nom
Wright, Gerard
Department département
Biochemistry and Biomedical Sciences
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2013
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
5201
Research subject group en
Microbiology
Research subject group fr
Microbiologie
Research subject en
Bacteriology
Research subject fr
Bactériologie
Partie
1
Nb partie
1
Application title
Evaluation and characterization of novel inhibitors of beta-lactamases
Keyword
NSERC
Application summary
Resistance to antibiotics is a growing crisis that has major implications for the healthcare, agricultural andpharmaceutical sectors. Despite a tremendous need for new drugs and there are few new leads being pursued bythe traditional large pharmaceutical industry. This void creats a great opportunity for Small to Medium sizedEntities (SMEs) in this area. NAEJA Pharmaceuticals of Edmonton, AB has developed a collection ofproprietary and novel lead molecules that inhibit ß-lactamases, enzymes that inactivate the penicillin,cephalosporin and penem antibiotics that represent ~50% of the antibiotic drugs in current clinical use. Suchinhibitory molecules could form the basis of drug formulations where the inhibitor of ß-lactamase enzymes isadministered together with a ß-lactam drug. This approach has proven clinical utility and has been successfullydeployed for the treatment of drug resistant infections including several ""blockbuster"" drug combinations suchas Augmentin (a combination of amoxicillin and the ß-lactamase inhibitor clavulanic acid). In order to movethese lead candidates forward, NAEJA needs to have a better understanding of the molecular mechanisms ofß-lactamase inhibition these compounds and their roles in blocking antibiotic resistance in cells, expertise thatis the core of over 20 years of research in the Wright lab. This new partnership will enable NAEJA to assessthe value of their lead molecules and select one as a clinical candidate for downstream drug development andclinical trials.